WAVE LIFE SCIENCES LTD SG9999014716 08/05/2025 TO APPROVE, BY A NON-BINDING ADVISORY VOTE, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT. SECTION 14A SAY-ON-PAY VOTES ISSUER 3155227 0 FOR 3155227 FOR 2 WAVE LIFE SCIENCES LTD SG9999014716 08/05/2025 TO APPROVE, ON A NON-BINDING, ADVISORY BASIS ONLY, THE FREQUENCY OF HOLDING FUTURE SHAREHOLDER ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 3155227 0 1 YEAR 3155227 FOR 2 DYNATRACE, INC. US2681501092 08/20/2025 NON-BINDING ADVISORY VOTE ON THE COMPENSATION OF DYNATRACE'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 50000 25229 ABSTAIN 50000 FOR 2 DECKERS OUTDOOR CORPORATION US2435371073 09/08/2025 TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DESCRIBED IN THE SECTION OF THE PROXY STATEMENT ENTITLED """"COMPENSATION DISCUSSION AND ANALYSIS."""" SECTION 14A SAY-ON-PAY VOTES ISSUER 2000 0 ABSTAIN 2000 FOR 2 CELLEBRITE DI LTD. IL0011794802 09/19/2025 TO APPROVE THE COMPENSATION PACKAGE FOR THOMAS E. HOGAN AS OUR CHIEF EXECUTIVE OFFICER. SECTION 14A SAY-ON-PAY VOTES ISSUER 80000 0 FOR 80000 FOR 2 WISE PLC GB00BL9YR756 09/25/2025 TO APPROVE THE DIRECTORS REMUNERATION REPORT SECTION 14A SAY-ON-PAY VOTES ISSUER 295906 0 ABSTAIN 295906 FOR 2 OSE IMMUNOTHERAPEUTICS SA FR0012127173 09/30/2025 APPROVAL OF THE REMUNERATION POLICY APPLICABLE TO THE CHIEF EXECUTIVE OFFICER SECTION 14A SAY-ON-PAY VOTES ISSUER 354858 0 FOR 354858 FOR 2 OSE IMMUNOTHERAPEUTICS SA FR0012127173 09/30/2025 APPROVAL OF THE REMUNERATION POLICY APPLICABLE TO THE DIRECTORS SECTION 14A SAY-ON-PAY VOTES ISSUER 354858 0 FOR 354858 FOR 2 OSE IMMUNOTHERAPEUTICS SA FR0012127173 09/30/2025 APPROVAL OF THE INFORMATION RELATING TO THE REMUNERATION OF THE CORPORATE OFFICERS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024, IN ACCORDANCE WITH SECTION I OF ARTICLE L. 22-10-9 OF THE FRENCH COMMERCIAL CODE SECTION 14A SAY-ON-PAY VOTES ISSUER 354858 0 FOR 354858 FOR 2 OSE IMMUNOTHERAPEUTICS SA FR0012127173 09/30/2025 APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL ELEMENTS MAKING UP THE TOTAL REMUNERATION AND BENEFITS OF ANY KIND PAID DURING OR ALLOCATED FOR THE PAST FINANCIAL YEAR TO THE CHIEF EXECUTIVE OFFICER SECTION 14A SAY-ON-PAY VOTES ISSUER 354858 0 FOR 354858 FOR 2 MEDIOBANCA - BANCA DI CREDITO FINANZIARIO S.P.A. IT0000062957 10/28/2025 REMUNERATION: REPORT ON THE REMUNERATION POLICY AND COMPENSATION PAID: SECTION I - REMUNERATION AND INCENTIVE POLICY OF THE MEDIOBANCA GROUP 2025-2026 SECTION 14A SAY-ON-PAY VOTES ISSUER 20000 0 ABSTAIN 20000 FOR 2 MEDIOBANCA - BANCA DI CREDITO FINANZIARIO S.P.A. IT0000062957 10/28/2025 REMUNERATION: 2025-2026 FINANCIAL INSTRUMENT-BASED INCENTIVE SYSTEM; ANNUAL PERFORMANCE SHARE PLAN SECTION 14A SAY-ON-PAY VOTES ISSUER 20000 0 ABSTAIN 20000 FOR 2 MEDIOBANCA - BANCA DI CREDITO FINANZIARIO S.P.A. IT0000062957 10/28/2025 REMUNERATION: REPORT ON THE REMUNERATION POLICY AND COMPENSATION PAID: NON-BINDING RESOLUTION ON SECTION II - DISCLOSURE OF COMPENSATION PAID IN THE 2024-2025 FINANCIAL YEAR SECTION 14A SAY-ON-PAY VOTES ISSUER 20000 0 ABSTAIN 20000 FOR 2 TESLA, INC. US88160R1014 11/06/2025 A TESLA PROPOSAL FOR A NON-BINDING ADVISORY VOTE APPROVING 2024 EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 2500 0 ABSTAIN 2500 FOR 2 IREN LIMITED AU0000185993 11/19/2025 APPROVE AN ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 20000 0 ABSTAIN 20000 FOR 2 IREN LIMITED AU0000185993 11/19/2025 APPROVE AN ADVISORY VOTE ON EXECUTIVE COMPENSATION (THE """"SAY-ON-PAY"""" VOTE)"""" SECTION 14A SAY-ON-PAY VOTES ISSUER 20000 0 ABSTAIN 20000 FOR 2 REZOLUTE, INC. US76200L3096 11/19/2025 TO APPROVE, BY A NON-BINDING ADVISORY VOTE, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE EXECUTIVE COMPENSATION SECTION OF THE PROXY STATEMENT. SECTION 14A SAY-ON-PAY VOTES ISSUER 4870000 0 FOR 4870000 FOR 2 INVENTIVA SA FR0013233012 11/27/2025 APPROVAL OF THE COMPENSATION POLICY FOR THE CHIEF EXECUTIVE OFFICER FOR THE 2025 FINANCIAL YEAR (FOR THE PERIOD FROM NOVEMBER 27 TO DECEMBER 31) SECTION 14A SAY-ON-PAY VOTES ISSUER 15945067 0 FOR 15945067 FOR 2 MICROSOFT CORPORATION US5949181045 12/05/2025 ADVISORY VOTE TO APPROVE NAMED EXECUTIVE OFFICER COMPENSATION (""""SAY-ON-PAY VOTE"""") SECTION 14A SAY-ON-PAY VOTES ISSUER 17150 0 ABSTAIN 17150 FOR 2 PALO ALTO NETWORKS, INC. US6974351057 12/09/2025 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 10576 874 ABSTAIN 10576 FOR 2 ZYMEWORKS INC. US98985Y1082 12/30/2025 ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS SECTION 14A SAY-ON-PAY VOTES ISSUER 2643446 10937 FOR 2643446 FOR 2 ZSCALER, INC. US98980G1022 01/12/2026 TO APPROVE ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 4999 0 ABSTAIN 4999 FOR 2 ZSCALER, INC. US98980G1022 01/12/2026 TO APPROVE ON A NON-BINDING, ADVISORY BASIS, THE FREQUENCY OF FUTURE STOCKHOLDER ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 4999 0 ABSTAIN 4999 FOR 2 INFINEON TECHNOLOGIES AG DE0006231004 02/19/2026 APPROVE REMUNERATION POLICY SECTION 14A SAY-ON-PAY VOTES ISSUER 184920 0 FOR 184920 FOR 2 QUALCOMM INCORPORATED US7475251036 03/17/2026 APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 23 13977 UNVOTED 0 FOR 2 QUALCOMM INCORPORATED US7475251036 03/17/2026 APPROVAL ON AN ADVISORY BASIS, OF THE FREQUENCY OF FUTURE VOTES ON OUR EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 23 13977 UNVOTED 0 FOR 2 ARROWHEAD PHARMACEUTICALS, INC. US04280A1007 03/19/2026 ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 1615476 0 FOR 1615476 FOR 2 GUBRA A/S DK0062266474 03/26/2026 APPROVE REMUNERATION REPORT (ADVISORY VOTE) SECTION 14A SAY-ON-PAY VOTES ISSUER 42282 0 FOR 42282 FOR 2 GUBRA A/S DK0062266474 03/26/2026 APPROVE GUIDELINES FOR INCENTIVE-BASED COMPENSATION FOR EXECUTIVE MANAGEMENT AND BOARD SECTION 14A SAY-ON-PAY VOTES ISSUER 42282 0 FOR 42282 FOR 2 ZEALAND PHARMA A/S DK0060257814 03/26/2026 APPROVE REMUNERATION REPORT (ADVISORY VOTE) SECTION 14A SAY-ON-PAY VOTES ISSUER 705000 0 FOR 705000 FOR 2 CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED CNE100006WS8 04/03/2026 TO CONSIDER AND APPROVE THE CONFIRMATION OF THE REMUNERATION OF DIRECTORS FOR 2025 AND THE REMUNERATION PLAN FOR 2026; SECTION 14A SAY-ON-PAY VOTES ISSUER 180000 0 FOR 180000 FOR 2 EGETIS THERAPEUTICS AB SE0003815604 04/14/2026 APPROVE REMUNERATION POLICY AND OTHER TERMS OF EMPLOYMENT FOR EXECUTIVE MANAGEMENT SECTION 14A SAY-ON-PAY VOTES ISSUER 3357615 0 FOR 3357615 FOR 2 EGETIS THERAPEUTICS AB SE0003815604 04/14/2026 APPROVE REMUNERATION REPORT SECTION 14A SAY-ON-PAY VOTES ISSUER 3357615 0 FOR 3357615 FOR 2 BROADCOM INC US11135F1012 04/20/2026 ADVISORY VOTE TO APPROVE THE NAMED EXECUTIVE OFFICER COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 26157 843 ABSTAIN 26157 FOR 2 VERISURE P.L.C. GB00BVMN1558 04/23/2026 APPROVE REMUNERATION REPORT SECTION 14A SAY-ON-PAY VOTES ISSUER 65000 0 ABSTAIN 65000 FOR 2 VERISURE P.L.C. GB00BVMN1558 04/23/2026 APPROVE REMUNERATION POLICY AND OTHER TERMS OF EMPLOYMENT FOR EXECUTIVE MANAGEMENT SECTION 14A SAY-ON-PAY VOTES ISSUER 65000 0 ABSTAIN 65000 FOR 2 BIOINVENT INTERNATIONAL AB SE0015244520 04/29/2026 APPROVE REMUNERATION REPORT SECTION 14A SAY-ON-PAY VOTES ISSUER 1506309 0 FOR 1506309 FOR 2 BIOINVENT INTERNATIONAL AB SE0015244520 04/29/2026 APPROVE REMUNERATION POLICY AND OTHER TERMS OF EMPLOYMENT FOR EXECUTIVE MANAGEMENT SECTION 14A SAY-ON-PAY VOTES ISSUER 1506309 0 FOR 1506309 FOR 2 LEXICON PHARMACEUTICALS, INC. US5288723027 04/30/2026 ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS SECTION 14A SAY-ON-PAY VOTES ISSUER 44303518 0 FOR 44303518 FOR 2 SAP SE DE0007164600 05/05/2026 APPROVE REMUNERATION REPORT SECTION 14A SAY-ON-PAY VOTES ISSUER 0 30000 UNVOTED 0 FOR 2 VICORE PHARMA HOLDING AB SE0007577895 05/06/2026 APPROVE REMUNERATION REPORT SECTION 14A SAY-ON-PAY VOTES ISSUER 13761412 0 FOR 13761412 FOR 2 ABIVAX SA FR0012333284 05/11/2026 APPROVAL OF THE ELEMENTS OF REMUNERATION MENTIONED IN ARTICLE L. 22-10-9 1 OF THE FRENCH COMMERCIAL CODE, PURSUANT TO ARTICLE L. 22-10-34 OF THE FRENCH COMMERCIAL CODE SECTION 14A SAY-ON-PAY VOTES ISSUER 4080955 0 FOR 4080955 FOR 2 ABIVAX SA FR0012333284 05/11/2026 APPROVAL OF THE ELEMENTS OF REMUNERATION PAID DURING OR AWARDED FOR THE 2025 FINANCIAL YEAR TO """"MR. MARC DE GARIDEL"""" DUE TO HIS MANDATE AS CHIEF EXECUTIVE OFFICER SECTION 14A SAY-ON-PAY VOTES ISSUER 4080955 0 FOR 4080955 FOR 2 ABIVAX SA FR0012333284 05/11/2026 APPROVAL OF THE INFORMATION ON THE REMUNERATION OF CORPORATE OFFICERS INCLUDED IN THE REPORT ON CORPORATE GOVERNANCE AND REFERRED TO IN ARTICLE L.22-10-9 1. OF THE FRENCH COMMERCIAL CODE SECTION 14A SAY-ON-PAY VOTES ISSUER 4080955 0 FOR 4080955 FOR 2 ABIVAX SA FR0012333284 05/11/2026 APPROVAL OF THE REMUNERATION POLICY APPLICABLE TO THE CHIEF EXECUTIVE OFFICER SECTION 14A SAY-ON-PAY VOTES ISSUER 4080955 0 FOR 4080955 FOR 2 AIXTRON SE DE000A0WMPJ6 05/13/2026 APPROVE REMUNERATION REPORT SECTION 14A SAY-ON-PAY VOTES ISSUER 0 42778 UNVOTED 0 FOR 2 ONWARD MEDICAL N.V. NL0015000HT4 05/13/2026 IMPLEMENTATION OF THE COMPENSATION POLICY OVER THE FINANCIAL YEAR 2025 (ADVISORY VOTE) SECTION 14A SAY-ON-PAY VOTES ISSUER 1799501 0 FOR 1799501 FOR 2 GENSIGHT BIOLOGICS SA FR0013183985 05/19/2026 APPROVAL OF THE COMPENSATION POLICY FOR THE CHIEF EXECUTIVE OFFICER AND/OR ANY OTHER EXECUTIVE CORPORATE OFFICER SECTION 14A SAY-ON-PAY VOTES ISSUER 23164131 0 FOR 23164131 FOR 2 GENSIGHT BIOLOGICS SA FR0013183985 05/19/2026 APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL COMPONENTS OF TOTAL COMPENSATION AND BENEFITS OF ANY KIND PAID DURING OR AWARDED IN RESPECT OF THE PAST FISCAL YEAR TO MS. LAURENCE RODRIGUEZ, CHIEF EXECUTIVE OFFICER SECTION 14A SAY-ON-PAY VOTES ISSUER 23164131 0 FOR 23164131 FOR 2 GENSIGHT BIOLOGICS SA FR0013183985 05/19/2026 APPROVAL OF THE INFORMATION REFERRED TO IN SECTION I OF ARTICLE L. 22-10-9 OF THE FRENCH COMMERCIAL CODE SECTION 14A SAY-ON-PAY VOTES ISSUER 23164131 0 FOR 23164131 FOR 2 AMAZON.COM, INC. US0231351067 05/20/2026 ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION SECTION 14A SAY-ON-PAY VOTES ISSUER 27680 18961 ABSTAIN 27680 FOR 2 JFROG LTD. IL0011684185 05/20/2026 TO APPROVE ON A NONBINDING, ADVISORY BASIS THE COMPENSATION PAID TO US TO OUR NAMED EXECUTIVE OFFICERS, AS DISLCOSED IN THE PROXY STATEMENT. SECTION 14A SAY-ON-PAY VOTES ISSUER 3922 124894 ABSTAIN 3922 FOR 2 JFROG LTD. IL0011684185 05/20/2026 AS REQUIRED BY THE ISRAELI COMPANIES LAW, TO APPROVE CHANGES TO THE COMPENSATION OF SHLOMI BEN HAIM, OUR CHIEF EXECUTIVE OFFICER. SECTION 14A SAY-ON-PAY VOTES ISSUER 3922 124894 ABSTAIN 3922 FOR 2 JFROG LTD. IL0011684185 05/20/2026 AS REQUIRED BY THE ISRAELI COMPANIES LAW, TO APPROVE CHANGES TO THE COMPENSATION OF YOAV LANDMAN, OUR CHIEF TECHNOLOGY OFFICER. SECTION 14A SAY-ON-PAY VOTES ISSUER 3922 124894 ABSTAIN 3922 FOR 2 CINCLUS PHARMA HOLDING AB SE0020388577 05/21/2026 APPROVE REMUNERATION REPORT SECTION 14A SAY-ON-PAY VOTES ISSUER 596862 0 FOR 596862 FOR 2 INNATE PHARMA SA FR0010331421 05/21/2026 APPROVE COMPENSATION OF JONATHAN DICKINSON, CEO FROM MAY 22, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 2778366 0 FOR 2778366 FOR 2 INNATE PHARMA SA FR0010331421 05/21/2026 APPROVE COMPENSATION REPORT OF CORPORATE OFFICERS SECTION 14A SAY-ON-PAY VOTES ISSUER 2778366 0 FOR 2778366 FOR 2 INNATE PHARMA SA FR0010331421 05/21/2026 APPROVE REMUNERATION POLICY OF CEO SECTION 14A SAY-ON-PAY VOTES ISSUER 2778366 0 FOR 2778366 FOR 2 INNATE PHARMA SA FR0010331421 05/21/2026 APPROVE REMUNERATION POLICY OF CORPORATE OFFICERS SECTION 14A SAY-ON-PAY VOTES ISSUER 2778366 0 FOR 2778366 FOR 2 INNATE PHARMA SA FR0010331421 05/21/2026 AUTHORIZE UP TO 150,000 SHARES FOR USE IN RESTRICTED STOCK PLANS RESERVED FOR CORPORATE OFFICERS SECTION 14A SAY-ON-PAY VOTES ISSUER 2778366 0 FOR 2778366 FOR 2 SERVICENOW, INC. US81762P1021 05/21/2026 ADVISORY VOTE TO APPROVE SERVICENOW'S NAMED EXECUTIVE OFFICER COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 1157 85933 ABSTAIN 1157 FOR 2 SERVICENOW, INC. US81762P1021 05/21/2026 ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE OFFICER COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 1157 85933 ABSTAIN 1157 FOR 2 EXOSENS FR001400Q9V2 05/22/2026 APPROVE REMUNERATION POLICY OF DIRECTORS SECTION 14A SAY-ON-PAY VOTES ISSUER 0 12500 UNVOTED 0 FOR 2 EXOSENS FR001400Q9V2 05/22/2026 APPROVE REMUNERATION POLICY OF JEROME CERISIER, CEO SECTION 14A SAY-ON-PAY VOTES ISSUER 0 12500 UNVOTED 0 FOR 2 EXOSENS FR001400Q9V2 05/22/2026 APPROVE COMPENSATION OF JEROME CERISIER, CEO SECTION 14A SAY-ON-PAY VOTES ISSUER 0 12500 UNVOTED 0 FOR 2 EXOSENS FR001400Q9V2 05/22/2026 APPROVE COMPENSATION REPORT SECTION 14A SAY-ON-PAY VOTES ISSUER 0 12500 UNVOTED 0 FOR 2 TRANSGENE SA FR0005175080 05/22/2026 APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL ITEMS COMPRISING THE TOTAL COMPENSATION AND BENEFITS OF ANY KIND PAID OR AWARDED FOR FINANCIAL YEAR 2025 TO MR. ALESSANDRO RIVA IN HIS CAPACITY AS CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF TRANSGENE SECTION 14A SAY-ON-PAY VOTES ISSUER 6122994 0 FOR 6122994 FOR 2 TRANSGENE SA FR0005175080 05/22/2026 APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL ITEMS COMPRISING THE TOTAL COMPENSATION AND BENEFITS OF ANY KIND PAID OR AWARDED FOR FINANCIAL YEAR 2025 TO MR. CHRISTOPHE ANCEL IN HIS CAPACITY AS DEPUTY CHIEF EXECUTIVE OFFICER OF TRANSGENE SECTION 14A SAY-ON-PAY VOTES ISSUER 6122994 0 FOR 6122994 FOR 2 TRANSGENE SA FR0005175080 05/22/2026 APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL ITEMS COMPRISING THE TOTAL COMPENSATION AND BENEFITS OF ANY KIND PAID OR AWARDED FOR FINANCIAL YEAR 2025 TO THE COMPANYS CORPORATE OFFICERS (THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER, THE DEPUTY CHIEF EXECUTIVE OFFICER AND THE DIRECTORS) SECTION 14A SAY-ON-PAY VOTES ISSUER 6122994 0 FOR 6122994 FOR 2 TRANSGENE SA FR0005175080 05/22/2026 APPROVAL OF THE ITEMS CONCERNING THE COMPENSATION POLICY FOR CORPORATE OFFICERS FOR FINANCIAL YEAR 2026 SECTION 14A SAY-ON-PAY VOTES ISSUER 6122994 0 FOR 6122994 FOR 2 TRANSGENE SA FR0005175080 05/22/2026 APPROVAL OF THE PRINCIPLES AND CRITERIA FOR DETERMINING, ALLOCATING AND GRANTING THE FIXED, VARIABLE AND EXCEPTIONAL ITEMS COMPRISING THE TOTAL COMPENSATION AND BENEFITS OF ANY KIND THAT MAY BE AWARDED IN FINANCIAL YEAR 2026 TO THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER SECTION 14A SAY-ON-PAY VOTES ISSUER 6122994 0 FOR 6122994 FOR 2 CYTOKINETICS, INCORPORATED US23282W6057 05/27/2026 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT. SECTION 14A SAY-ON-PAY VOTES ISSUER 500000 0 FOR 500000 FOR 2 NEUMORA THERAPEUTICS, INC. US6409791000 05/27/2026 ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 8495648 2174 FOR 8495648 FOR 2 NEUMORA THERAPEUTICS, INC. US6409791000 05/27/2026 ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 8495648 2174 1 YEAR 8495648 FOR 2 SPYRE THERAPEUTICS INC. US00773J2024 05/27/2026 TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 818598 0 FOR 818598 FOR 2 ADYEN N.V. NL0012969182 05/28/2026 FINANCIAL YEAR 2025: PROPOSAL TO ADVISE ON THE REMUNERATION REPORT (ADVISORY VOTE) SECTION 14A SAY-ON-PAY VOTES ISSUER 0 8220 UNVOTED 0 FOR 2 PHARMING GROUP NV NL0010391025 05/28/2026 APPROVE REMUNERATION REPORT SECTION 14A SAY-ON-PAY VOTES ISSUER 2099999 1 FOR 2099999 FOR 2 WORKIVA INC. US98139A1051 05/28/2026 APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF WORKIVA'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 67122 25378 UNVOTED 0 FOR 2 HANSA BIOPHARMA AB SE0002148817 06/01/2026 PROPOSAL REGARDING GUIDELINES FOR EXECUTIVE REMUNERATION SECTION 14A SAY-ON-PAY VOTES ISSUER 1966267 0 FOR 1966267 FOR 2 TAYSHA GENE THERAPIES, INC. US8776191061 06/01/2026 TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 8829913 0 FOR 8829913 FOR 2 TAYSHA GENE THERAPIES, INC. US8776191061 06/01/2026 TO INDICATE, ON A NON-BINDING ADVISORY BASIS, THE PREFERRED FREQUENCY OF FUTURE STOCKHOLDER ADVISORY VOTES ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 8829913 0 1 YEAR 8829913 FOR 2 XENON PHARMACEUTICALS INC CA98420N1050 06/02/2026 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE CORPORATION'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 1318564 0 FOR 1318564 FOR 2 XENON PHARMACEUTICALS INC CA98420N1050 06/02/2026 TO APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF FUTURE SHAREHOLDER ADVISORY VOTES TO APPROVE THE COMPENSATION OF THE CORPORATION'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 1318564 0 1 YEAR 1318564 FOR 2 AELIS FARMA FR0014007ZB4 06/03/2026 APPROVAL OF THE ELEMENTS OF COMPENSATION PAID DURING OR ALLOCATED BY WAY OF THE FINANCIAL YEAR 2025 TO THE CHIEF EXECUTIVE OFFICE SECTION 14A SAY-ON-PAY VOTES ISSUER 173021 0 ABSTAIN 173021 FOR 2 AELIS FARMA FR0014007ZB4 06/03/2026 APPROVAL OF THE REMUNERATION POLICY APPLICABLE TO THE CHIEF EXECUTIVE OFFICER SECTION 14A SAY-ON-PAY VOTES ISSUER 173021 0 ABSTAIN 173021 FOR 2 DBV TECHNOLOGIES S.A. US23306J3095 06/03/2026 APPROVAL OF THE INFORMATION SET OUT IN SECTION I OF ARTICLE L.22-10-9 OF THE FRENCH COMMERCIAL CODE ON THE COMPENSATION OF CORPORATE OFFICERS FOR THE YEAR ENDED DECEMBER 31, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 1647528 209834 FOR 1647528 FOR 2 DBV TECHNOLOGIES S.A. US23306J3095 06/03/2026 APPROVAL OF THE FIXED, VARIABLE AND NON-RECURRING COMPONENTS OF OVERALL COMPENSATION AND BENEFITS OF ALL TYPES PAID OR ASSIGNED DURING THE YEAR ENDED DECEMBER 31, 2025, TO MR. DANIEL TASSE, CHIEF EXECUTIVE OFFICER SECTION 14A SAY-ON-PAY VOTES ISSUER 1647528 209834 FOR 1647528 FOR 2 DBV TECHNOLOGIES S.A. US23306J3095 06/03/2026 ADVISORY OPINION ON THE COMPENSATION OF NAMED EXECUTIVE OFFICERS OTHER THAN THE CHIEF EXECUTIVE OFFICER SECTION 14A SAY-ON-PAY VOTES ISSUER 1647528 209834 FOR 1647528 FOR 2 DBV TECHNOLOGIES S.A. US23306J3095 06/03/2026 APPROVAL OF THE COMPENSATION POLICY FOR THE CHIEF EXECUTIVE OFFICER AND DEPUTY CHIEF EXECUTIVE OFFICER FOR THE YEAR ENDING DECEMBER 31, 2026 SECTION 14A SAY-ON-PAY VOTES ISSUER 1647528 209834 FOR 1647528 FOR 2 DBV TECHNOLOGIES SA FR0010417345 06/03/2026 APPROVAL OF THE INFORMATION SET OUT IN SECTION I OF ARTICLE L.22-10-9 OF THE FRENCH COMMERCIAL CODE ON THE COMPENSATION OF CORPORATE OFFICERS FOR THE YEAR ENDED DECEMBER 31, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 10023195 0 FOR 10023195 FOR 2 DBV TECHNOLOGIES SA FR0010417345 06/03/2026 APPROVAL OF THE FIXED, VARIABLE AND NON-RECURRING COMPONENTS OF OVERALL COMPENSATION AND BENEFITS OF ALL TYPES PAID OR ASSIGNED DURING THE YEAR ENDED DECEMBER 31, 2025, TO MR. DANIEL TASSE, CHIEF EXECUTIVE OFFICER SECTION 14A SAY-ON-PAY VOTES ISSUER 10023195 0 FOR 10023195 FOR 2 DBV TECHNOLOGIES SA FR0010417345 06/03/2026 ADVISORY OPINION ON THE COMPENSATION OF NAMED EXECUTIVE OFFICERS OTHER THAN THE CHIEF EXECUTIVE OFFICER SECTION 14A SAY-ON-PAY VOTES ISSUER 10023195 0 FOR 10023195 FOR 2 DBV TECHNOLOGIES SA FR0010417345 06/03/2026 APPROVAL OF THE COMPENSATION POLICY FOR THE CHIEF EXECUTIVE OFFICER AND DEPUTY CHIEF EXECUTIVE OFFICER FOR THE YEAR ENDING DECEMBER 31, 2026 SECTION 14A SAY-ON-PAY VOTES ISSUER 10023195 0 FOR 10023195 FOR 2 DENALI THERAPEUTICS INC. US24823R1059 06/03/2026 ADVISORY VOTE ON EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 1396513 0 FOR 1396513 FOR 2 KALARIS THERAPEUTICS INC US4829291065 06/03/2026 THE APPROVAL OF AN ADVISORY VOTE ON EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 400102 35696 FOR 400102 FOR 2 KALARIS THERAPEUTICS INC US4829291065 06/03/2026 THE HOLDING OF AN ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES. SECTION 14A SAY-ON-PAY VOTES ISSUER 400102 35696 1 YEAR 400102 FOR 2 STOKE THERAPEUTICS, INC. US86150R1077 06/03/2026 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 1995347 0 FOR 1995347 FOR 2 TREVI THERAPEUTICS INC US89532M1018 06/03/2026 APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 1786867 0 FOR 1786867 FOR 2 AMYLYX PHARMACEUTICALS, INC. US03237H1014 06/04/2026 TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 1084738 145262 FOR 1084738 FOR 2 EDGEWISE THERAPEUTICS INC US28036F1057 06/04/2026 CONDUCT AN ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 4330263 0 FOR 4330263 FOR 2 GOSSAMER BIO, INC. US38341P1021 06/04/2026 APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT. SECTION 14A SAY-ON-PAY VOTES ISSUER 5118074 90894 FOR 5118074 FOR 2 TANGO THERAPEUTICS, INC. US87583X1090 06/04/2026 TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 5674758 0 FOR 5674758 FOR 2 ALPHABET INC. US02079K3059 06/05/2026 ADVISORY VOTE TO APPROVE COMPENSATION AWARDED TO NAMED EXECUTIVE OFFICERS SECTION 14A SAY-ON-PAY VOTES ISSUER 62703 0 ABSTAIN 62703 FOR 2 DYNE THERAPEUTICS, INC. US26818M1080 06/05/2026 TO VOTE, ON AN ADVISORY BASIS, TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 2021069 208056 FOR 2021069 FOR 2 BYD COMPANY LTD CNE100000296 06/09/2026 TO CONSIDER AND APPROVE THE AMENDMENTS TO THE REMUNERATION MANAGEMENT POLICY FOR DIRECTORS AND SENIOR MANAGEMENT OF THE COMPANY SECTION 14A SAY-ON-PAY VOTES ISSUER 496800 0 UNVOTED 0 FOR 2 COGENT BIOSCIENCES, INC. US19240Q2012 06/09/2026 APPROVAL, ON A NON-BINDING, ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 1709279 0 FOR 1709279 FOR 2 ENLIVEN THERAPEUTICS, INC. US29337E1029 06/09/2026 TO APPROVE, IN AN ADVISORY (NON-BINDING) VOTE, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN OUR PROXY STATEMENT. SECTION 14A SAY-ON-PAY VOTES ISSUER 746226 0 FOR 746226 FOR 2 ENLIVEN THERAPEUTICS, INC. US29337E1029 06/09/2026 TO APPROVE, IN AN ADVISORY (NON-BINDING) VOTE, THE FREQUENCY OF FUTURE STOCKHOLDER ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 746226 0 1 YEAR 746226 FOR 2 NANOBIOTIX SA FR0011341205 06/09/2026 APPROVAL OF THE ELEMENTS OF THE REMUNERATION DUE OR GRANTED FOR THE 2025 FISCAL YEAR TO THE CHAIRMAN OF THE EXECUTIVE COMMITTEE, MR. LAURENT LEVY SECTION 14A SAY-ON-PAY VOTES ISSUER 4483275 0 FOR 4483275 FOR 2 NANOBIOTIX SA FR0011341205 06/09/2026 APPROVAL OF THE ELEMENTS OF REMUNERATION DUE OR GRANTED FOR THE 2025 FISCAL YEAR TO MRS. ANNE-JULIETTE HERMANT, REGARDING HER MANDATE AS A MEMBER OF THE EXECUTIVE COMMITTEE AND HER EMPLOYMENT CONTRACT SECTION 14A SAY-ON-PAY VOTES ISSUER 4483275 0 FOR 4483275 FOR 2 NANOBIOTIX SA FR0011341205 06/09/2026 APPROVAL OF THE ELEMENTS OF REMUNERATION OWED OR GRANTED FOR THE 2025 FINANCIAL YEAR TO MR. BARTHOLOMEUS VAN RHIJN, REGARDING HIS MANDATE AS A MEMBER OF THE EXECUTIVE COMMITTEE AND HIS EMPLOYMENT CONTRACT SECTION 14A SAY-ON-PAY VOTES ISSUER 4483275 0 FOR 4483275 FOR 2 NANOBIOTIX SA FR0011341205 06/09/2026 APPROVAL OF THE ELEMENTS OF THE REMUNERATION DUE OR GRANTED FOR THE 2025 FINANCIAL YEAR TO MR. LOUIS KAYITALIRE REGARDING HIS MANDATE AS A MEMBER OF THE EXECUTIVE COMMITTEE AND HIS EMPLOYMENT CONTRACT SECTION 14A SAY-ON-PAY VOTES ISSUER 4483275 0 FOR 4483275 FOR 2 NANOBIOTIX SA FR0011341205 06/09/2026 APPROVAL OF THE REMUNERATION POLICY FOR MR. LAURENT LEVY DUE TO HIS MANDATE AS CHAIRMAN OF THE EXECUTIVE COMMITTEE FOR THE 2026 FISCAL YEAR SECTION 14A SAY-ON-PAY VOTES ISSUER 4483275 0 FOR 4483275 FOR 2 NANOBIOTIX SA FR0011341205 06/09/2026 APPROVAL OF THE REMUNERATION POLICY OF MRS. ANNE-JULIETTE HERMANT DUE TO HER POSITION AS A MEMBER OF THE EXECUTIVE COMMITTEE AND HER EMPLOYMENT CONTRACT FOR THE 2026 FISCAL YEAR SECTION 14A SAY-ON-PAY VOTES ISSUER 4483275 0 FOR 4483275 FOR 2 NANOBIOTIX SA FR0011341205 06/09/2026 APPROVAL OF THE REMUNERATION POLICY FOR MR. BARTHOLOMEUS VAN RHIJN DUE TO HIS MANDATE AS A MEMBER OF THE EXECUTIVE COMMITTEE AND HIS EMPLOYMENT CONTRACT FOR THE 2026 FINANCIAL YEAR SECTION 14A SAY-ON-PAY VOTES ISSUER 4483275 0 FOR 4483275 FOR 2 NANOBIOTIX SA FR0011341205 06/09/2026 APPROVAL OF THE REMUNERATION POLICY OF MR. LOUIS KAYITALIRE DUE TO HIS MANDATE AS A MEMBER OF THE EXECUTIVE COMMITTEE AND HIS EMPLOYMENT CONTRACT FOR THE 2026 FISCAL YEAR SECTION 14A SAY-ON-PAY VOTES ISSUER 4483275 0 FOR 4483275 FOR 2 TABOOLA.COM LTD. IL0011754137 06/09/2026 TO APPROVE AN ADVISORY PROPOSAL ON EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 9969495 0 UNVOTED 0 FOR 1 TABOOLA.COM LTD. IL0011754137 06/09/2026 TO APPROVE THE COMPENSATION POLICY FOR THE COMPANY'S EXECUTIVE OFFICERS AND DIRECTORS. SECTION 14A SAY-ON-PAY VOTES ISSUER 9969495 0 UNVOTED 0 FOR 1 TABOOLA.COM LTD. IL0011754137 06/09/2026 TO APPROVE THE COMPENSATION TERMS FOR OUR CHIEF EXECUTIVE OFFICER (AND DIRECTOR). SECTION 14A SAY-ON-PAY VOTES ISSUER 9969495 0 UNVOTED 0 FOR 1 KORRO BIO, INC. US5009461089 06/10/2026 NON-BINDING ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 347718 0 FOR 347718 FOR 2 MEDIAN TECHNOLOGIES FR0011049824 06/10/2026 SETTING OF THE COMPENSATION AMOUNT ALLOCATED IN RESPECT OF THE DUTIES OF DIRECTOR (ARTICLE L. 225-45 OF THE FRENCH COMMERCIAL CODE) SECTION 14A SAY-ON-PAY VOTES ISSUER 752397 0 FOR 752397 FOR 2 PALISADE BIO, INC. US6963894026 06/10/2026 TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT. SECTION 14A SAY-ON-PAY VOTES ISSUER 2000000 0 FOR 2000000 FOR 2 PALVELLA THERAPEUTICS, INC US6979471090 06/10/2026 APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 247192 10293 FOR 247192 FOR 2 PALVELLA THERAPEUTICS, INC US6979471090 06/10/2026 APPROVAL, ON AN ADVISORY BASIS, OF THE PREFERRED FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 247192 10293 1 YEAR 247192 FOR 2 REMITLY GLOBAL, INC. US75960P1049 06/10/2026 TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 1543271 0 UNVOTED 0 FOR 1 SOLID BIOSCIENCES INC. US83422E2046 06/10/2026 THE APPROVAL OF AN ADVISORY VOTE ON EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 7690405 0 FOR 7690405 FOR 2 UNIQURE N.V. NL0010696654 06/10/2026 APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPANY. SECTION 14A SAY-ON-PAY VOTES ISSUER 440698 59302 FOR 440698 FOR 2 UNIQURE N.V. NL0010696654 06/10/2026 APPROVAL, ON AN ADVISORY BASIS, OF THE FREQUENCY OF ADVISORY VOTES ON THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPANY. SECTION 14A SAY-ON-PAY VOTES ISSUER 440698 59302 1 YEAR 440698 FOR 2 ANNEXON, INC. US03589W1027 06/11/2026 TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 3958646 0 FOR 3958646 FOR 2 ARCUS BIOSCIENCES, INC. US03969F1093 06/11/2026 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT. SECTION 14A SAY-ON-PAY VOTES ISSUER 1612077 0 UNVOTED 0 FOR 1 ARCUS BIOSCIENCES, INC. US03969F1093 06/11/2026 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT. SECTION 14A SAY-ON-PAY VOTES ISSUER 1395000 0 FOR 1395000 FOR 2 BEONE MEDICINES, LTD. (FKA BEIGENE) US07725L1026 06/11/2026 THAT, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT, FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 BE AND IS HEREBY APPROVED. SECTION 14A SAY-ON-PAY VOTES ISSUER 465000 0 FOR 465000 FOR 2 BEONE MEDICINES, LTD. (FKA BEIGENE) US07725L1026 06/11/2026 THAT, THE MAXIMUM AGGREGATE COMPENSATION FOR THE EXECUTIVE MANAGEMENT TEAM FOR FISCAL YEAR 2027 BE AND IS HEREBY APPROVED. SECTION 14A SAY-ON-PAY VOTES ISSUER 465000 0 FOR 465000 FOR 2 BEONE MEDICINES, LTD. (FKA BEIGENE) US07725L1026 06/11/2026 THAT, ON AN ADVISORY BASIS, THE SWISS STATUTORY COMPENSATION REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 BE AND IS HEREBY APPROVED. SECTION 14A SAY-ON-PAY VOTES ISSUER 465000 0 FOR 465000 FOR 2 MEDLINE INC. US58507V1070 06/11/2026 ADVISORY VOTE TO APPROVE OUR EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 25000 0 FOR 25000 FOR 2 MEDLINE INC. US58507V1070 06/11/2026 ADVISORY VOTE ON THE FREQUENCY OF VOTES ON OUR EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 25000 0 1 YEAR 25000 FOR 2 WHITEHAWK THERAPEUTICS, INC. US00032Q1040 06/11/2026 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS IDENTIFIED IN THE 2025 SUMMARY COMPENSATION TABLE IN THE """"EXECUTIVE COMPENSATION"""" SECTION OF THE PROXY STATEMENT. SECTION 14A SAY-ON-PAY VOTES ISSUER 2082000 0 FOR 2082000 FOR 2 DATADOG, INC. US23804L1035 06/15/2026 ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 6 54294 FOR 6 FOR 2 AGENUS INC. US00847G8042 06/16/2026 TO APPROVE, IN A NON-BINDING ADVISORY VOTE, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS FOR 2025 (SAY-ON-PAY). SECTION 14A SAY-ON-PAY VOTES ISSUER 1064250 0 FOR 1064250 FOR 2 CULLINAN THERAPEUTICS, INC. US2300311063 06/16/2026 PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 1193410 0 FOR 1193410 FOR 2 IONQ, INC. US46222L1089 06/16/2026 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS IN 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 170000 0 UNVOTED 0 FOR 1 MAAT PHARMA FR0012634822 06/16/2026 APPROVAL OF THE ELEMENTS OF COMPENSATION MENTIONED IN ARTICLE L. 22-10-9 I OF THE FRENCH COMMERCIAL CODE, PURSUANT TO ARTICLE L. 22-10-34 OF THE FRENCH COMMERCIAL CODE SECTION 14A SAY-ON-PAY VOTES ISSUER 866802 9891 FOR 866802 FOR 2 MAAT PHARMA FR0012634822 06/16/2026 APPROVAL OF THE ELEMENTS OF COMPENSATION PAID DURING OR ALLOCATED BY WAY OF THE FINANCIAL YEAR 2025 TO THE CHIEF EXECUTIVE OFFICER SECTION 14A SAY-ON-PAY VOTES ISSUER 866802 9891 FOR 866802 FOR 2 MAAT PHARMA FR0012634822 06/16/2026 APPROVAL OF THE REMUNERATION POLICY APPLICABLE TO THE CHIEF EXECUTIVE OFFICER SECTION 14A SAY-ON-PAY VOTES ISSUER 866802 9891 FOR 866802 FOR 2 SILENCE THERAPEUTICS PLC US82686Q1013 06/16/2026 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THIS PROXY STATEMENT. SECTION 14A SAY-ON-PAY VOTES ISSUER 2851908 59530 FOR 2851908 FOR 2 SILENCE THERAPEUTICS PLC US82686Q1013 06/16/2026 TO APPROVE OUR DIRECTORS' REMUNERATION REPORT FOR THE YEAR ENDED DECEMBER 31, 2025, WHICH IS SET FORTH AS ANNEX A TO THE PROXY STATEMENT AND ON PAGES 32 TO 54 OF THE 2025 U.K. ANNUAL REPORT). SECTION 14A SAY-ON-PAY VOTES ISSUER 2851908 59530 FOR 2851908 FOR 2 BICYCLE THERAPEUTICS PLC US0887861088 06/17/2026 TO APPROVE, ON ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT. SECTION 14A SAY-ON-PAY VOTES ISSUER 1560882 0 FOR 1560882 FOR 2 BICYCLE THERAPEUTICS PLC US0887861088 06/17/2026 TO APPROVE OUR DIRECTORS' REMUNERATION REPORT FOR THE YEAR ENDED DECEMBER 31, 2025 (THE """"DIRECTORS' REMUNERATION REPORT""""), WHICH IS SET FORTH AS ANNEX A TO THE PROXY STATEMENT (EXCLUDING THE DIRECTORS' REMUNERATION POLICY SET OUT ON PAGES A-3 TO A-22 OF THE DIRECTORS' REMUNERATION REPORT AND REFERENCED IN PROPOSAL 9 BELOW). SECTION 14A SAY-ON-PAY VOTES ISSUER 1560882 0 FOR 1560882 FOR 2 CYTOMX THERAPEUTICS, INC. US23284F1057 06/17/2026 TO APPROVE, ON A NONBINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT ACCOMPANYING THIS NOTICE OF ANNUAL MEETING OF STOCKHOLDERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 3457711 0 FOR 3457711 FOR 2 CYTOMX THERAPEUTICS, INC. US23284F1057 06/17/2026 TO HOLD A NON-BINDING ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES BY STOCKHOLDERS ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 3457711 0 1 YEAR 3457711 FOR 2 DAMORA THERAPEUTICS, INC. US36322Q2066 06/17/2026 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 900000 0 FOR 900000 FOR 2 DAMORA THERAPEUTICS, INC. US36322Q2066 06/17/2026 TO CONDUCT AN ADVISORY VOTE TO DETERMINE THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 900000 0 1 YEAR 900000 FOR 2 GITLAB INC. US37637K1088 06/17/2026 APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION PAID BY GITLAB INC. TO ITS NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 84099 15901 FOR 84099 FOR 2 MADRIGAL PHARMACEUTICALS INC. US5588681057 06/17/2026 ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION SECTION 14A SAY-ON-PAY VOTES ISSUER 21400 0 FOR 21400 FOR 2 OLEMA PHARMACEUTICALS, INC. US68062P1066 06/17/2026 APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 4856949 0 FOR 4856949 FOR 2 STRUCTURE THERAPEUTICS, INC. US86366E1064 06/17/2026 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT. SECTION 14A SAY-ON-PAY VOTES ISSUER 1293423 0 FOR 1293423 FOR 2 BUSY MING GROUP CO., LTD. CNE100007DZ1 06/18/2026 TO CONSIDER AND APPROVE THE REMUNERATION PLAN FOR DIRECTORS OF THE COMPANY FOR THE YEAR ENDING DECEMBER 31, 2026 SECTION 14A SAY-ON-PAY VOTES ISSUER 43300 0 ABSTAIN 43300 FOR 2 CRINETICS PHARMACEUTICALS, INC. US22663K1079 06/18/2026 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT PURSUANT TO THE COMPENSATION DISCLOSURE RULES OF THE SECURITIES AND EXCHANGE COMMISSION SECTION 14A SAY-ON-PAY VOTES ISSUER 1753609 50027 FOR 1753609 FOR 2 DISC MEDICINE, INC. US2546041011 06/18/2026 TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 988401 0 FOR 988401 FOR 2 ORIC PHARMACEUTICALS, INC. US68622P1093 06/18/2026 TO APPROVE, ON AN ADVISORY BASIS, EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 1007575 0 UNVOTED 0 FOR 1 ORIC PHARMACEUTICALS, INC. US68622P1093 06/18/2026 TO APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 1007575 0 UNVOTED 0 FOR 1 ORIC PHARMACEUTICALS, INC. US68622P1093 06/18/2026 TO APPROVE, ON AN ADVISORY BASIS, EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 1990617 0 FOR 1990617 FOR 2 ORIC PHARMACEUTICALS, INC. US68622P1093 06/18/2026 TO APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 1990617 0 1 YEAR 1990617 FOR 2 REVOLUTION MEDICINES, INC. US76155X1000 06/18/2026 TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT PURSUANT TO THE COMPENSATION DISCLOSURE RULES OF THE SECURITIES AND EXCHANGE COMMISSION (""""SAY-ON-PAY""""). SECTION 14A SAY-ON-PAY VOTES ISSUER 1060000 0 FOR 1060000 FOR 2 MONOPAR THERAPEUTICS, INC. US61023L2079 06/22/2026 TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS ON AN ADVISORY, NON-BINDING BASIS. SECTION 14A SAY-ON-PAY VOTES ISSUER 223190 0 FOR 223190 FOR 2 FOGHORN THERAPEUTICS INC. US3441741077 06/24/2026 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF FOGHORN'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 712794 7206 FOR 712794 FOR 2 FOGHORN THERAPEUTICS INC. US3441741077 06/24/2026 TO APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF FOGHORN'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 712794 7206 1 YEAR 712794 FOR 2 FULCRUM THERAPEUTICS INC US3596161097 06/24/2026 A NON-BINDING ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 2400000 0 FOR 2400000 FOR 2 KYMERA THERAPEUTICS, INC. US5015751044 06/24/2026 TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 2986830 0 FOR 2986830 FOR 2 NVIDIA CORPORATION US67066G1040 06/24/2026 ADVISORY APPROVAL OF OUR EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 50165 38920 FOR 50165 FOR 2 OSE IMMUNOTHERAPEUTICS SA FR0012127173 06/24/2026 APPROVAL OF THE ELEMENTS OF THE REMUNERATION DUE OR AWARDED FOR THE 2025 FISCAL YEAR TO MR. MARC LE BOZEC IN RESPECT OF HIS MANDATE AS MANAGING DIRECTOR FOR THE PERIOD FROM OCTOBER 2, 2025, TO DECEMBER 31, 2025 (EX-POST VOTE) SECTION 14A SAY-ON-PAY VOTES ISSUER 194174 0 ABSTAIN 194174 FOR 2 OSE IMMUNOTHERAPEUTICS SA FR0012127173 06/24/2026 APPROVAL OF THE ELEMENTS OF REMUNERATION DUE OR GRANTED FOR THE 2025 FISCAL YEAR TO MR. NICOLAS POIRIER IN HIS CAPACITY AS MANAGING DIRECTOR, FOR THE PERIOD FROM JANUARY 1, 2025, TO OCTOBER 2, 2025 (EX-POST VOTE) SECTION 14A SAY-ON-PAY VOTES ISSUER 194174 0 ABSTAIN 194174 FOR 2 OSE IMMUNOTHERAPEUTICS SA FR0012127173 06/24/2026 VOTE ON THE INFORMATION REGARDING THE 2025 REMUNERATION OF CORPORATE OFFICERS (EXCLUDING MANAGING CORPORATE OFFICERS) UNTIL SEPTEMBER 30, 2025, MENTIONED IN ARTICLE L. 22-10-9 OF THE FRENCH COMMERCIAL CODE (EX-POST VOTE) SECTION 14A SAY-ON-PAY VOTES ISSUER 194174 0 ABSTAIN 194174 FOR 2 OSE IMMUNOTHERAPEUTICS SA FR0012127173 06/24/2026 VOTE ON THE INFORMATION RELATING TO THE 2025 REMUNERATION OF CORPORATE OFFICERS (EXCLUDING MANAGING CORPORATE OFFICERS) BETWEEN SEPTEMBER 30, 2025, AND DECEMBER 31, 2025, MENTIONED IN ARTICLE L.22-10-9 OF THE COMMERCIAL CODE (EX-POST VOTE) SECTION 14A SAY-ON-PAY VOTES ISSUER 194174 0 ABSTAIN 194174 FOR 2 OSE IMMUNOTHERAPEUTICS SA FR0012127173 06/24/2026 APPROVAL OF THE REMUNERATION POLICY OF MR. MARC LE BOZEC, MANAGING DIRECTOR, FOR THE 2026 FISCAL YEAR (EX-ANTE VOTE) SECTION 14A SAY-ON-PAY VOTES ISSUER 194174 0 ABSTAIN 194174 FOR 2 OSE IMMUNOTHERAPEUTICS SA FR0012127173 06/24/2026 APPROVAL OF THE REMUNERATION POLICY FOR CORPORATE OFFICERS (EXCLUDING MANAGING CORPORATE OFFICERS) FOR THE 2026 FISCAL YEAR (EX-ANTE VOTE) SECTION 14A SAY-ON-PAY VOTES ISSUER 194174 0 ABSTAIN 194174 FOR 2 RHYTHM PHARMACEUTICALS, INC. US76243J1051 06/24/2026 APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPANY. SECTION 14A SAY-ON-PAY VOTES ISSUER 1136275 0 FOR 1136275 FOR 2 VALNEVA SE FR0004056851 06/25/2026 APPROVAL OF THE COMPENSATION POLICY APPLICABLE TO MR. THOMAS LINGELBACH, CEO, FOR THE FISCAL YEAR 2026 SECTION 14A SAY-ON-PAY VOTES ISSUER 2700514 365885 FOR 2700514 FOR 2 INHIBIKASE THERAPEUTICS, INC. US45719W2052 06/26/2026 TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 5850000 0 FOR 5850000 FOR 2 INHIBIKASE THERAPEUTICS, INC. US45719W2052 06/26/2026 TO VOTE, ON A NON-BINDING, ADVISORY BASIS, ON THE FREQUENCY OF FUTURE NON-BINDING, ADVISORY VOTES ON COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 5850000 0 1 YEAR 5850000 FOR 2 VTV THERAPEUTICS INC. US9183852048 06/26/2026 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 163000 0 UNVOTED 0 FOR 2 VICTORY GIANT TECHNOLOGY (HUIZHOU)CO LTD CNE100007JY1 06/29/2026 TO CONSIDER AND APPROVE THE AMENDMENTS OF SOME GOVERNANCE RULES OF THE COMPANY: TO CONSIDER AND APPROVE THE AMENDMENTS TO THE REMUNERATION SYSTEM FOR DIRECTORS AND SENIOR MANAGEMENT SECTION 14A SAY-ON-PAY VOTES ISSUER 10000 0 ABSTAIN 10000 FOR 2 INVENTIVA SA FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. FREDERIC CREN IN HIS CAPACITY AS CHIEF EXECUTIVE OFFICER UNTIL SEPTEMBER 30, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 15875484 0 FOR 15875484 FOR 2 INVENTIVA SA FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. ANDREW OBENSHAIN IN HIS CAPACITY AS CHIEF EXECUTIVE OFFICER FROM OCTOBER 1ST, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 15875484 0 FOR 15875484 FOR 2 INVENTIVA SA FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. PIERRE BROQUA IN HIS CAPACITY AS DEPUTY CHIEF EXECUTIVE OFFICER UNTIL JUNE 30, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 15875484 0 FOR 15875484 FOR 2 INVENTIVA SA FR0013233012 06/30/2026 APPROVAL OF THE INFORMATION ON CORPORATE OFFICERS COMPENSATION INCLUDED IN THE CORPORATE GOVERNANCE REPORT AND REFERRED TO IN ARTICLE L.22-10-9 I. OF THE FRENCH COMMERCIAL CODE SECTION 14A SAY-ON-PAY VOTES ISSUER 15875484 0 FOR 15875484 FOR 2 INVENTIVA SA FR0013233012 06/30/2026 APPROVAL OF THE COMPENSATION POLICY FOR MR. ANDREW OBENSHAIN IN HIS CAPACITY AS CHIEF EXECUTIVE OFFICER SECTION 14A SAY-ON-PAY VOTES ISSUER 15875484 0 FOR 15875484 FOR 2